Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Immerge BioTherapeutics announces identification of PERV receptor


Important step forward for safety of xenotransplantation

This week in the Proceedings of the National Academy of Sciences, researchers from Immerge BioTherapeutics, Inc., announced that they have identified the receptors that are used by porcine endogenous retrovirus (PERV) in order to enter and infect a cell (PNAS; May 27, 2003; vol. 100, no. 11; 6759-6764). This is a critical discovery because it allows scientists to begin to develop strategies to prevent PERV replication. PERV has been considered a key safety issue in the development of xenotransplantation using pig organs because the virus has shown the ability to infect some human cells in laboratory tissue cultures. The study was performed in a collaborative effort between Immerge and the academic groups of Professors Robin Weiss, University College, London, UK and Daniel Salomon, The Scripps Research Institute, La Jolla, CA.

"Our identification of the PERV receptor is a major step forward because it allows us to address fundamental aspects of the biology of this virus," said Dr Clive Patience, Director of the Safety Program at Immerge. "For instance, PERV has grown in only three of approximately 40 human cell lines that we and others have tested. To date, we have not understood why most human cells do not support PERV growth. We can now begin to address this type of fundamental issue."

PERV is a virus that all pigs are born with, which poses no harm to the pig itself. However, unlike other viruses, which can be eliminated either through breeding or raising pigs in a clean lab environment, multiple copies of PERV form part of the normal genomic DNA of pigs and are therefore passed from one generation to the next.

"PERV is of concern in developing xenotransplantation of porcine organs towards an accepted procedure in clinical medicine," commented Professor Robin Weiss from University College, London. "We need to understand the basic virology of PERV, and indeed other porcine microorganisms, before xenotransplantation can be considered a safe procedure."

There is a critical need to identify new sources of organs for the growing number of people needing life-saving transplants around the world. In the U.S. alone, there are more than 81,000 people on the waiting list for organs and an unknown number of additional people needing organs who did not qualify for the transplant list because of age, illness or other issues.

"There is an unmet need in clinical transplantation for donors, and the availability of acceptable porcine organs could solve this huge demand" said Professor Dan Salomon from The Scripps Research Institute. "It remains important to identify the risk of a potentially infectious agent to both the patient receiving a transplant as well as others. Our identification of the PERV receptors will allow us to begin to address this issue."

As part of its progress toward clinical xenotransplantation, Immerge BioTherapeutics Inc. has developed a safety program with a number of international expert collaborators. The depth of Immerge’s safety program is unique among companies conducting xenotransplantation research. The company has previously reported the identification of animals within its miniature swine herd that do not transmit PERV to human cell lines (Oldmixon et al. Journal of Virology 2002; 76: 3045-3048). In the past year, in collaborative efforts with the University of Missouri-Columbia and Infigen, Inc., Immerge also announced the birth of cloned, double knock-out miniature swine that lack expression of the GGTA1 gene. This gene is responsible for rapid rejection of organs and makes the animal organs more compatible for potential human transplant.

Immerge BioTherapeutics was formed on September 26, 2000, as a joint venture between Novartis Pharma AG and BioTransplant Incorporated. The company, which began operations on January 2, 2001, focuses its research efforts toward developing therapeutic applications for xenotransplantation.

Susan Hayes | EurekAlert!

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Earlier flowering of modern winter wheat cultivars

20.03.2018 | Agricultural and Forestry Science

Smithsonian researchers name new ocean zone: The rariphotic

20.03.2018 | Life Sciences

Molecular doorstop could be key to new tuberculosis drugs

20.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>